ROS1 (G2032R)
Sign in to save this workspaceROS1 · Variant type: point · HGVS: p.G2032R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Repotrectinib | 99.9% | 0.1% | 84.21 |
| 2 | Brigatinib | 99.1% | 0.9% | 82.96 |
| 3 | Lorlatinib | 99.0% | 1.0% | 97.24 |
| 4 | Ceritinib | 95.0% | 5.0% | 95.44 |
| 5 | Entrectinib | 93.0% | 7.0% | 93.69 |
| 6 | Crizotinib | 92.0% | 8.0% | 91.39 |
| 7 | Cabozantinib | 90.0% | 10.1% | 92.73 |
| 8 | Gilteritinib | 80.8% | 19.2% | 88.97 |
| 9 | Fostamatinib | 80.3% | 19.7% | 96.74 |
| 10 | Tivozanib | 79.0% | 21.0% | 92.42 |
| 11 | Lazertinib | 49.4% | 50.6% | 97.47 |
| 12 | Defactinib | 48.7% | 51.3% | 92.68 |
| 13 | Pralsetinib | 44.2% | 55.8% | 93.43 |
| 14 | Axitinib | 34.2% | 65.8% | 93.23 |
| 15 | Alpelisib | 33.9% | 66.1% | 97.22 |
| 16 | Pacritinib | 33.4% | 66.6% | 88.64 |
| 17 | Fedratinib | 29.6% | 70.4% | 96.21 |
| 18 | Ponatinib | 26.7% | 73.3% | 78.23 |
| 19 | Ruxolitinib | 25.2% | 74.8% | 98.25 |
| 20 | Pazopanib | 24.1% | 75.9% | 97.49 |
| 21 | Baricitinib | 21.9% | 78.1% | 97.99 |
| 22 | Osimertinib | 20.2% | 79.8% | 97.24 |
| 23 | Imatinib | 15.0% | 85.0% | 99.00 |
| 24 | Pexidartinib | 14.2% | 85.8% | 99.49 |
| 25 | Upadacitinib | 12.8% | 87.2% | 97.98 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Repotrectinib | 99.9% | — | — |
| Brigatinib | 99.1% | — | — |
| Lorlatinib | 99.0% | — | — |
| Ceritinib | 95.0% | — | — |
| Entrectinib | 93.0% | — | — |
| Crizotinib | 92.0% | — | — |
| Cabozantinib | 90.0% | — | — |
| Gilteritinib | 80.8% | — | — |
| Fostamatinib | 80.3% | — | — |
| Tivozanib | 79.0% | — | — |
| Lazertinib | 49.4% | — | — |
| Defactinib | 48.7% | — | — |
| Pralsetinib | 44.2% | — | — |
| Axitinib | 34.2% | — | — |
| Alpelisib | 33.9% | — | — |
| Pacritinib | 33.4% | — | — |
| Fedratinib | 29.6% | — | — |
| Ponatinib | 26.7% | — | — |
| Ruxolitinib | 25.2% | — | — |
| Pazopanib | 24.1% | — | — |
| Baricitinib | 21.9% | — | — |
| Osimertinib | 20.2% | — | — |
| Imatinib | 15.0% | — | — |
| Pexidartinib | 14.2% | — | — |
| Upadacitinib | 12.8% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.2ms